<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="molecules-25-02529-t004" orientation="portrait" position="float">
 <object-id pub-id-type="pii">molecules-25-02529-t004_Table 4</object-id>
 <label>Table 4</label>
 <caption>
  <p>Approval/trial status and side effect of the evaluated drugs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Inhibitors</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CheMBL ID</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Industry</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Most Common Side Effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
     <bold>HCV protease inhibitors</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Asunaprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL2105735</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III clinical trials [
     <xref rid="B41-molecules-25-02529" ref-type="bibr">41</xref>] 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bristol-Myers Squibb</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally well tolerated, increased ALT/AST [
     <xref rid="B42-molecules-25-02529" ref-type="bibr">42</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Danoprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL2311191</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in China 2018</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ascletis by Roche</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Faldaprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL1241348</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III clinical trials in 2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boehringer-Ingelheim</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal events [
     <xref rid="B43-molecules-25-02529" ref-type="bibr">43</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Narlaprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL1255891</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schering, â„ž-Pharm</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnancy lactation, severe neutropenia [
     <xref rid="B44-molecules-25-02529" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Sovaprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL2105750</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigational, received Fast Track status from FDA in 2012</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Achillion Pharmaceuticals</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Telaprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL231813</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vertex Pharmaceuticals and Johnson &amp; Johnson</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rash, anemia, leukopenia/neutropenia [
     <xref rid="B44-molecules-25-02529" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Vaniprevir</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL599872</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved Japan 2014</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck &amp; Co.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea, nausea [
     <xref rid="B45-molecules-25-02529" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="14" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
     <bold>DPP-4 inhibitors</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Alogliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL376359</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2013</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Takeda Pharmaceutical Company</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased risk of heart failure [
     <xref rid="B46-molecules-25-02529" ref-type="bibr">46</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Anagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Japan 2012</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanwa Kagaku Kenkyusho</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Dutogliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenomix Corporation</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not known yet</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Evogliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL1779710</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2015</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dong-A ST</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Headache, nasopharyngitis, upper respiratory tract infection [
     <xref rid="B47-molecules-25-02529" ref-type="bibr">47</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Gemigliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LG Life Sciences</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally well tolerated</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Gosogliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Russia 2016</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfizer</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypoglycemia [
     <xref rid="B48-molecules-25-02529" ref-type="bibr">48</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Linagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL237500</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2011</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eli Lilly and Company and Boehringer Ingelheim</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angioedema, pancreatitis, joint pain [
     <xref rid="B49-molecules-25-02529" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Melogliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glenmark Pharmaceuticals and Merck KGaA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not known yet</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Omarigliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL2105762</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Japan 2012</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck &amp; Co.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally well tolerated</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Saxagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL385517</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2009</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bristol-Myers Squibb; AstraZeneca</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper respiratory tract infection, may cause joint pain [
     <xref rid="B49-molecules-25-02529" ref-type="bibr">49</xref>,
     <xref rid="B50-molecules-25-02529" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Sitagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL1422</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2006</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck &amp; Co.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Headache, swelling of the legs, upper respiratory tract infection [
     <xref rid="B51-molecules-25-02529" ref-type="bibr">51</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Teneligliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Japan 2012</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mitsubishi Tanabe Pharma</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally well tolerated</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Trelagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Japan 2015</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Takeda</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generally well tolerated</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Vildagliptin</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL142703</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2007</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novartis</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nausea, hypoglycemia, headache, dizziness [
     <xref rid="B52-molecules-25-02529" ref-type="bibr">52</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
     <bold>Î±-Thrombin inhibitors</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Argatroban</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL1166</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2002</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eagle Pharmaceuticals</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bleeding from the bladder, blurred vision, chest pain, dizziness, fever [
     <xref rid="B53-molecules-25-02529" ref-type="bibr">53</xref>] 
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Inogatran</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL114715</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2016</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AstraZeneca</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well tolerated</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Melagatran</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AstraZeneca</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Dabigatran</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL539697</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2010</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Boehringer-Ingelheim</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastrointestinal [
     <xref rid="B54-molecules-25-02529" ref-type="bibr">54</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Apixaban</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL231779</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2014</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bristol-Myers Squibb and Pfizer</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bleeding, bausea [
     <xref rid="B55-molecules-25-02529" ref-type="bibr">55</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Betrixaban</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChEMBL512351</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2017</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Millennium Pharmaceuticals, Merk</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bleeding [
     <xref rid="B56-molecules-25-02529" ref-type="bibr">56</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Edoxaban</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHEBI:85973</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved 2015</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daiichi Sankyo</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stomach ache, abnormal results of blood tests that measure liver function, anemia [
     <xref rid="B57-molecules-25-02529" ref-type="bibr">57</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Otamixaban</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ended at phase III</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sanofi</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
